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ABSTRACT 
SDRNT1BIO Investigators 2020, 'Diabetic neuropathy is a substantial burden in people with type 1 diabetes 
and is strongly associated with socioeconomic disadvantage: A population-representative study from 
Scotland', Diabetes Care, vol. 43, no. 4, pp. 734-742. https://doi.org/10.2337/dc19-1582
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Objective: To assess the contemporaneous prevalence of diabetic peripheral neuropathy 
(DPN) in people with type 1 diabetes (T1D) in Scotland and study its cross-sectional 
association with risk factors and other diabetic complications. 
Research design and methods: We analyzed data from a large representative sample 
of adults with T1D (N=5,558). We assessed the presence of symptomatic neuropathy 
using the dichotomized (≥4) Michigan Screening Instrument Patient Questionnaire score. 
Logistic regression models were used to investigate associations between DPN and risk 
factors, as well as with other complications. 
Results: The burden of DPN is substantial with 13% prevalence overall. Adjusting for 
attained age, diabetes duration and sex, the odds of DPN increased mainly with waist-
hip ratio, lipids, poor glycemic control (OR 1.51 95% CI [1.21 - 1.89] for levels of 75 vs 53 
mmol/mol), ever vs. never smoking (1.67 [1.37-2.03]), worse renal function (1.96 [1.03-
3.74] for eGFR levels <30 vs. ≥90 ml/min/1.73m²). The odds significantly decreased with 
HDL-cholesterol (0.77 [0.66-0.89] per mmol/L). Living in more deprived areas was 
associated with DPN, (2.17 [1.78, 2.65]) for more vs. less deprived areas adjusted for 
other risk factors). Finally, individuals with prevalent DPN were much more likely than 
others to have other diabetes complications. 
Conclusions: Diabetic neuropathy remains substantial, particularly affecting those in the 
most socioeconomically deprived groups. Those with clinically manifest neuropathy also 
have a higher burden of other complications and elevated levels of modifiable risk factors. 
These data suggest that there is considerable scope to reduce neuropathy rates and 
narrow the socioeconomic differential by better risk factor control.  
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Neuropathy is a major complication of diabetes that results from nerve damage and has 
diverse manifestations (1). One of the most common manifestations is diabetic peripheral 
neuropathy (DPN), the symptoms of which depend on the class of sensory fibers involved. 
The typical DPN is distal symmetrical polyneuropathy, which is defined by the Toronto 
Diabetic Neuropathy Expert Group as “a symmetrical length-dependent sensorimotor 
polyneuropathy attributable to metabolic and microvessel alterations as a result of chronic 
hyperglycemia exposure (diabetes) and cardiovascular risk covariates” (2). The majority 
of patients with DPN may remain asymptomatic (1); others experience pain, loss of 
sensation, which in turn increases the risk of injury, falls, fractures, foot ulceration and 
thereby amputation. Hence, patients suffering from DPN experience a deterioration of 
their quality of life (1,3,4). 
Current guidelines recommend testing for temperature or pinprick sensation, vibration 
perception and using the 10-g monofilament to test for risk of foot ulceration (5–7). The 
tests only detect neuropathy at an advanced stage (8,9).   
There is currently no approved treatment specifically targeted at prevention of DPN. 
Current guidelines such as the American Diabetes Association’s 2019 Standards of Care 
(7) only recommend tight glycemic control in patients with Type 1 diabetes. This 
recommendation mainly stems from the results of the Diabetes Control and Complications 
Trial (DCCT) (10,11). Drug treatment of DPN mainly comprises symptom control using 
anticonvulsants and antidepressants (7,12,13), with duloxetine and pregabalin being 
among the first-line therapies indicated in the major guidelines (14). There are no 
neuropathy specific preventive or curative drugs.  
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Risk factor management has changed over the past decade with new tools of glycemic 
control being available such as pumps and continuous glucose monitoring; the landscape 
of complications has also changed. For example, diabetes is no longer the leading cause 
of blindness in England and Wales (15); the incidence of lower extremity amputations in 
Scotland has reduced (16). Therefore, in order to have up-to-date guidelines and policy, 
it is important to capture a current picture of the burden of clinically manifest neuropathy 
as well as of the risk factors and other diabetes complications associated with neuropathy. 
Neuropathy is one of the most difficult complications to define epidemiologically since the 
clinical screening examination is time consuming to conduct at epidemiological scale. 
Here we used the Michigan Neuropathy Screening Instrument Patient Questionnaire 
(MNSIQ) (17) to derive a picture of the current burden of symptomatic DPN across age 
and sociodemographic strata in a large nationally representative sample of people with 
type 1 diabetes. Finally, we explored the association of symptomatic DPN with potential 
risk factors and its clustering with other diabetes complications.  
Research design and methods 
The Scottish Diabetes Research Network Type 1 Bioresource (SDRNT1BIO) is a large 
cohort (N=6,127) of adults aged 16 years and older, recruited between December 2010 
and November 2013 across Scotland. The Bioresource consists of patients with type 1 
diabetes (T1DM), MODY (Maturity Onset diabetes of the Young) or LADA (Latent 
autoimmune diabetes of adults. The patients were current insulin users and had started 
insulin within 1 year of diagnosis. This cohort and its representativeness of the national 
adult population with Type 1 diabetes has been previously described: the SDRNT1BIO 
cohort was shown to have similar characteristics to those of the national population with 
6 
 
Type 1 diabetes for whom we also have data on many clinical characteristics but 
unfortunately not on the MNSI (18). Baseline data including a self-report questionnaire 
were collected at study date, and linked, both retrospectively and prospectively, to routine 
electronic health care data. The questionnaire included the MNSIQ. These linked data 
included diabetes related information from the Scottish Care Information-Diabetes 
Mellitus (SCI-DM) database (19), the Scottish Renal Registry and routine data from 
Information Services Division Scotland such as hospital admissions data (Scottish 
Morbidity Record SMR01). The data linkage and these data sources have been described 
in detail in Akbar et al (18). In brief, SCI-DM captures routine clinical encounters (>99%) 
of those with a diagnostic code of diabetes nationally. This includes the Scottish foot 
screening program which aims to assess the risk of developing foot ulceration in diabetes 
patients. The annual screening involves the use of a 10-g monofilament test plus the 
evaluation of the foot for ulceration and the possible development of a Charcot joint. (20). 
However, due to high levels of absence of data available at this time, it was not possible 
to use these to help define DPN. 
Assessment of symptomatic DPN 
We defined symptomatic DPN based on the MNSIQ (17), using the validated threshold 
of a MNSIQ score of 4 or more (21) as evidence of the presence of symptomatic DPN; 
this criterion was also used in a recent study to define DPN (22). We also estimated the 
proportion of patients with painful neuropathy, defined as a MNSIQ score of 4 or more 
combined with a positive answer to the MNSIQ item: “Do you ever have any burning pain 
in your legs and/or feet?” 
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We evaluated the proportion of patients who had been hospitalized for diabetic 
neuropathy, using ICD-10 and ICD-9 codes for diabetes with neurological complications. 
We also evaluated the proportion of those who had ever had Charcot joint based on the 
foot screening records.  
Risk factors 
We explored associations with known risk factors for microvascular disease and other 
factors previously reported as potentially related to DPN.  
Height (cm), weight (Kg), waist (cm) and hip (cm) measures were taken on study date as 
described in Akbar et al. (18). The albuminuria status on study day was derived as 
described in Bermingham et al. (23). Information on alcohol consumption was self-
reported in a patient questionnaire, the typical weekly consumption of alcohol was used 
in our analyses. Measurements for other risk factors were obtained through the linked 
data: HbA1c (mmol/mol), triglycerides (mmol/L), total Cholesterol (mmol/L), HDL 
Cholesterol (mmol/L), LDL Cholesterol (mmol/L), smoking status (ever smoker); eGFR 
levels (mL/min/1.73m2) were computed using the CKD Epidemiology Collaboration 
formula eGFR (24). Baseline measure was taken as the closest measure to study date 
within a one year window (from 365 days pre to 365 days post study date). Due to the 
high variability in blood pressure measurements, we used the mean value within this 
window for both systolic and diastolic blood pressure (mmHg). 
Complications 
Retinopathy status at baseline was obtained from the Scottish Diabetic Retinopathy 
Screening Programme (DRS) records, plus via SCI-DC, retaining the closest measurable 
8 
 
screening record within the time-frame set above. The grades measured and their 
meaning were described previously in Looker et al. (25), with the grading of the worst eye 
being used. Finally, for the purposes of the analyses, all stages of retinopathy were 
grouped together (mild, moderate or any of the referable states). A history of prior 
cardiovascular disease (CVD) at baseline was extracted from linked hospital admissions 
data having occurred before the study date and involving ICD-9 and ICD-10 codes for: 
ischemic heart disease, cerebrovascular disease, transient cerebral ischemic attacks, 
heart failure, cardiac arrhythmia, hypertensive disease, diabetes with circulatory 
complications. A history of prior peripheral vascular disease (PVD) at baseline was 
extracted from linked hospital admissions data having occurred before the study date and 
involving ICD-9 and ICD-10 codes for: amputations below the knee (leg, foot or toe), 
peripheral arterial disease, OPCS3 and OPCS4 codes for revascularization procedures, 
as well as any ulceration or below-knee amputation recorded prior to consent date in the 
SCI-DC foot screening. 
The acute complications of diabetes considered were severe hypoglycemia and diabetic 
ketoacidosis (DKA). We combined information from the patient questionnaire and SMR01 
data to define a recent history (within 12 months preceding study date), thus replicating 
the timeframe used by Tesfaye et al. (26) for DKA or hypoglycemia: any self-reported 
history or hospital admissions involving the ICD-10 codes: E10.1 to E14.1 for DKA; E16.0 
to E16.2 and E15 for hypoglycemia (in SMR01 data). Finally, nephropathy was crudely 
defined as the presence of micro or macroalbuminuria or eGFR levels lower than 60 
mL/min/1.73m2. 
Socio-economic status  
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An area-level indicator of socioeconomic status, the Scottish Index of Multiple Deprivation 
quintiles (SIMD2012) (27) was used, based on the patient’s postcode from SCI-DC 
database extract performed in 2014. The first and fifth SIMD quintiles represent the most 
and least deprived areas respectively. 
Statistical analysis 
All analyses were conducted using R version 3.3.3-64 bit (28). Significance was based 
on a level of 0.05. 
We presented the crude overall prevalence rate of symptomatic DPN, using as 
denominator the overall study cohort size or the age-sex stratum size as appropriate. In 
order to allow for international comparisons we also presented directly age-standardized 
prevalences, by applying our age and sex specific prevalence estimates to the European 
Standard Population 2013. Both overall and strum specific age-standardized prevalences 
and associated 95% confidence intervals were calculated using the R epitools package 
version 0.5-10 (29). Finally, we performed simple sensitivity analyses, using MNSIQ 
thresholds of 2 and 3 to define symptomatic DPN, and presented the crude overall 
prevalence obtained. We used multivariable logistic regression models to investigate the 
associations between potential risk factors and symptomatic DPN, entering all clinically 
relevant risk factors simultaneously and adjusting for age at baseline, diabetes duration 
at baseline and sex. We performed complete-case analyses, including only variables with 
less than 10% missingness (model M1), we then performed sensitivity analyses setting 
the missingness threshold for variable inclusion to 20% (model M2). Non-linearity of the 
relationship between continuous covariates and the log-odds of symptomatic DPN was 
investigated using restricted cubic spines, implemented through the R rms package 
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version 5.1-3 (30). A gradual step-up approach was used to complexify the model, first 
including only the adjustment variable and then using all the variables from model M1: a 
spline was considered for each continuous variable in turn and the best model retained 
at each stage was selected based on the AIC criterion, using the rules of thumb from 
Burnham et al. (31). The more complex model was only retained if the corresponding drop 
in AIC was of more than two compared to the best model from the previous stage. We 
used four knots for fitting the splines, located at Harrell’s recommended quantiles (30). 
The association between having symptomatic DPN and presenting with other diabetes 
complications was examined using a multinomial logistic regression (R package nnet 
version 7.3-12) with the number of other complications as outcome and symptomatic DPN 
as covariate, adjusting for age at baseline, diabetes duration at baseline and sex. 
Results of the logistic regression models are presented in terms of odds-ratios (OR) and 
associated 95% Confidence Intervals (CI). 
Results 
Prevalence 
The analyzed cohort consisted of 5,558 individuals with T1D and an available 
dichotomized MNSIQ score. At baseline, they had a median age of 44.7 years and a 
median diabetes duration of 20.5 years, 44.1% were female. None of the patients were 
recorded as having had Charcot on the foot screening program (data not shown), 11.2% 
of those with symptomatic DPN had ever had a hospital admission for neuropathy whilst 
46.7% of them were taking one of the drugs recommended by guidelines for DPN 
symptom control (32,33) - amitriptyline, duloxetine, gabapentin, pregabalin or capsaicin 
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cream 0.075% (Table 1). Finally, amongst the 715 patients with symptomatic DPN, 483 
patients (67.6%) met the definition of painful neuropathy (data not shown). 
The age-standardized prevalence rates of symptomatic DPN by age band and sex are 
illustrated in Figure 1 and detailed in Supplementary Table S1.The overall crude 
prevalence rate was estimated as 12.9%, the age-standardized prevalence did not differ: 
12.9% (95%CI 11.8-16.0). When using thresholds of 3 and 2 to define symptomatic DPN, 
the overall crude prevalence rates rose to respectively 19.4% and 35.2%.Figure 1 shows 
that the prevalence based on MNSIQ is higher for females than males in the younger age 
bands and higher for males in the higher age bands (from 45 years onwards). Overall, 
the prevalence of symptomatic DPN generally increased with age, apart from the oldest 
age band, where it decreased The lower point prevalence estimate over 75 years, 
particularly in women, may reflect higher death rates in those with DPN since of course 
prevalence rates will reflect a combination of age-specific incidence rates and death rates. 
Also, as shown in Supplementary Table S1, there is uncertainty around estimates in the 
oldest age band. 
Risk factors  
The baseline cohort characteristics are presented by symptomatic DPN status, and 
overall in Table 1. Those with symptomatic DPN were more likely to be older, have longer 
diabetes duration and live in more deprived areas. Being on a long-term prescription for 
aspirin, statin or anti-hypertensive drugs was more common in those with symptomatic 
DPN and the crude levels of many cardiovascular risk factors were higher. As shown in 
Table 2, age and diabetes duration were significantly associated with symptomatic DPN. 
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Adjusted for age and diabetes duration, the odds of symptomatic DPN for females vs. 
males was 1.0.  
The multivariable model 1 for symptomatic DPN fitted risk factors simultaneously. Model 
2 further included triglycerides and albuminuria in those in whom these data were 
available. LDL-C was not evaluated as almost 50% were missing these data. As shown 
in Table 2 adjusted for age, diabetes duration and gender, higher BMI, waist-hip ratio, 
total cholesterol, triglycerides, ever smoked, lower levels of eGFR (vs levels ≥90), 
albuminuria,  current used of aspirin, statin and anti-hypertensive were associated with 
higher odds of symptomatic DPN. Higher levels of HDL-cholesterol, and higher weekly 
consumption of alcohol (vs consumption <2 units/week) were associated with lower odds 
of symptomatic DPN. When these risk factors were entered into a model simultaneously, 
the associations with DPN remained similar, apart from current use of statin therapy which 
was no longer associated with DPN.  
As shown in Figure S1 using restricted cubic splines, the relationship between HbA1c 
levels and the odds of having DPN was found to be non-linear, with odds of DPN 
becoming significantly higher only with very elevated HbA1c levels (from around 65 
mmol/mol i.e. 8.1%), compared to controlled levels of 53 mmol/mol (7.0%). 
A non-linear relationship was also found between the odds of having DPN and systolic 
blood pressure: the odds were higher only for lower systolic blood pressure (compared to 





Socio-economic status  
Adjusted for age, gender and diabetes duration, individuals who lived in more deprived 
areas had significantly higher odds of having DPN than those living in less deprived areas 
(2.61 [2.21 – 3.08]). Following adjustment for other risk factors, this association remained 
(2.17[1.78 – 2.65]).  
Complications  
The distribution of other diabetic complications by DPN status is presented in 
supplementary Table S2: for each of the complications considered, the proportion of 
individuals with each complication was consistently higher among those with DPN. We 
examined the clustering of diabetic complications in relation to neuropathy in the N=4,514 
for whom information on all complications was available. Figure 2 shows the distribution 
of the number of other diabetic complications by age band and neuropathy status. At all 
ages, multiple complications were more common in those with neuropathy and the 
number of multiple complications increased with age. 
The multinomial logistic regression model adjusting for age, sex and diabetes duration 
confirmed that patients with DPN were more likely to present with other diabetes 
complications compared to those without neuropathy: (2.62 [2.00; 3.42] for one other 
diabetes complication versus none and 10.53 [8.08; 13.71] for 2 or more other 
complications versus none). 
Conclusions  
In this study we found that symptomatic diabetic peripheral neuropathy is a common 
problem in those with type 1 diabetes despite modern standards of care. We found a large 
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socioeconomic gradient with those in the more deprived groups being at almost three 
times the risk. Moreover we found very strong associations with modifiable risk factors. 
We also found that symptomatic DPN clusters strongly with other complications since 
those with DPN are much more likely than those without to also have retinopathy, CVD, 
renal disease and be at risk of acute complications.  
This study is, to the best of our knowledge, the largest contemporaneous study of 
symptomatic DPN in adults with Type 1 diabetes. The prevalence of DPN amongst this 
representative sample of adults with Type 1 diabetes in Scotland, was estimated as 
12.9%. We have had to rely on symptomatic measures in our large epidemiological 
setting, with the dichotomized MNSIQ score used having a reported sensitivity of 40% 
(21). This definition was likely to underestimate the prevalence of symptomatic DPN and 
we performed sensitivity analyses using MNSIQ thresholds of 3 and 2, leading to the 
higher crude prevalence estimates of 19.4% and 35.2%, respectively. Hence, the key 
message is that symptomatic neuropathy which is only the tip of the iceberg, remains 
common. 
DPN prevalence estimates reported in the literature are highly variable as different studies 
assessed the presence of neuropathy using different methods, and focus on different 
populations (e.g. youth, community-based or hospital based-settings) (1,4,14,34). 
Jaiswal et al. (35) reported a prevalence of 7% in youth with T1D from the SEARCH for 
Diabetes youth study using the clinical examination from the Michigan Neuropathy 
Screening Instrument, which is comparable to our estimated prevalence of 5.6% in the 
lowest age band (16 to 25 years old). Tesfaye et al. (26) reported, a 28% prevalence in 
the EURODIAB IDDM Complications study. They measured neuropathy based on a 
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combination of symptoms, clinical and neurophysiological assessments in a group of 
clinic-attending insulin-dependent patients aged 15 to 60 (36). The prevalence identified 
using our methodology are therefore consistent with the data from these studies.  
We investigated the clinical risk factors cross-sectionally associated with prevalent DPN 
and found similar results to findings from the literature (1,4,26,37,38). DPN was cross-
sectionally associated with poor glycemic control, smoking, higher lipids and poor renal 
function whilst HDL-Cholesterol was inversely associated. We did not find a linear 
association with glycaemia in our data but the risks of DPN rose steeply above HbA1c 
levels of 65 mmol/mol (8.1%), and we note that 63% of our cohort was above these levels. 
We did not replicate previous associations with higher blood pressures but 
antihypertensive usage was high and was highest in those with DPN. We also found 
counter-intuitive results with lower weekly alcohol consumption being associated to higher 
odds of DPN, we believe this is because about half of the individuals with DPN are on 
drugs used for neuropathy, and avoidance of alcohol consumption is often recommended 
with these.  
Our associations are cross-sectional and do not demonstrate causality per se. However, 
they are very similar to prospective studies such as Tesfaye et al. (11) that have 
highlighted such a causal role. Indeed, although current guidelines mainly focus on tight 
glycemic control (7), others such as Tesfaye et al. (11,35) have also emphasized the 
control of other risk factors and smoking cessation in preventing and ameliorating DPN. 
A key message from our data is that even in people with symptomatic disease, there 
remains inadequate control of risk factors and therefore that opportunities for reducing 
disease burden are being missed.  
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SIMD was strongly associated with symptomatic DPN, with individuals living in deprived 
areas having much higher odds of having DPN. This association remained strong even 
after including the clinical risk factors in the model. Hence, possible poor risk factor control 
in the more deprived population would not suffice to explain the disparity in the odds of 
DPN. This emphasizes the need to tackle the unmet burden of risk factors in those with 
poorer social circumstances. It is also important to consider that conditional upon the 
presence or absence of disease, the responses to the MNSIQ could vary by social 
deprivation, levels of education and the quality of local service-provision. If clinical 
detection rates were lower, for example, in the most deprived, then the response to 
question 9 from the MNSIQ “Has your doctor ever told you that you have diabetic 
neuropathy” could be biased downwards; hence the true association between 
symptomatic DPN and deprivation could be stronger than what we were able to capture 
in our study. Our findings regarding the cross-sectional risk factor associations with DPN 
demonstrate that neuropathy risk is not some fixed inevitable consequence of diabetes in 
particular individuals but rather is highly subject to modifiable factors.  
The clustering of symptomatic DPN with other chronic complications was striking in our 
data. This demonstrates the importance of not just considering one complication at a time 
but the importance of the overall management of risk and the potential interplay of 
complications on life quality in the individual with diabetes. The data reinforce previous 
findings (26) and give support to the idea of a holistic, comprehensive approach to 
diabetes management.  
We found a higher prevalence of recent DKA and hypoglycemia in those with DPN. These 
data suggest that diagnosed neuropathy identifies a group at higher risk of acute 
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metabolic complications. Hence, structured education, which has been shown to be 
beneficial in terms of DKA and hypoglycemia (39), might be targeted at this group.  
The main limitation of the study is that we did not have resources or the fieldwork time to 
carry out extensive clinical examination for more subtle levels of neuropathy. Also, our 
risk factor association analysis is cross-sectional since we only have the MNSIQ score at 
a single time point. The strengths of our study are the use of a standardized questionnaire 
instrument, its contemporaneous nature, its population representativeness and the wide 
range of risk factors measured.  
In summary, the burden of neuropathy remains substantial in this population of adults 
with Type 1 diabetes, and there is substantial scope for risk factor modification in those 
with DPN. Patients need to have a comprehensive support which is holistic in terms of 
diabetes care as they are likely to present several concurrent complications. Finally, the 
significant association of socio-economic status in the likelihood of having DPN indicates 
an urgent need to tackle inequalities in health within Type 1 diabetes patients.  
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Table 1 – Baseline characteristics of the study population by DPN status  
Parameter No DPN DPN Total Completeness N (%) 
Total Included 4843 (87.1) 715 (12.9) 5558  
Attained age (years) at baseline 43.7 (32.0, 54.4) 50.6 (41.0, 59.3) 44.7 (33.0, 55.2) 5558(100.0) 
Diabetes duration (years) 19.8 (10.7, 30.1) 26.9 (16.1, 37.4) 20.5 (11.1, 31.0) 5558(100.0) 
Sex: Female 2129 (44.0) 320 (44.8) 2449 (44.1) 5558(100.0) 
SIMD quintile: Q1-Q2 (most deprived) 1419 (29.5) 346 (48.7) 1765 (32.0) 5518(99.3) 
HbA1c (mmol/mol) 68.0 (60.0, 79.0) 76.0 (66.0, 89.0) 69.0 (60.0, 80.0) 5499(98.9) 
HbA1c (%) 8.4 (7.6, 9.4) 9.1 (8.2, 10.3) 8.5 (7.6, 9.5) 5499(98.9) 
Systolic blood pressure (mmHg) 129.9 (121.8, 138.7) 132.8 (122.1, 143.8) 130.2 (121.9, 139.4) 5524(99.4) 
Diastolic blood pressure (mmHg) 75.5 (70.6, 80.5) 75.0 (70.2, 80.1) 75.5 (70.6, 80.4) 5525(99.4) 
Weight (kg) 76.5 (66.9, 87.4) 77.9 (66.5, 91.0) 76.7 (66.8, 87.8) 5456(98.2) 
Height (cm) 171.0 (164.0, 178.0) 170.0 (163.0, 175.1) 170.8 (164.0, 177.5) 5517(99.3) 
BMI (kg/m2) 26.1 (23.4, 29.2) 26.9 (23.7, 31.2) 26.2 (23.4, 29.5) 5448(98.0) 
Waist-hip ratio 0.9 (0.8, 0.9) 0.9 (0.9, 1.0) 0.9 (0.8, 0.9) 5498(98.9) 
Total Cholesterol (mmol/L) 4.5 (4.0, 5.2) 4.6 (3.9, 5.3) 4.5 (4.0, 5.2) 5413(97.4) 
Triglycerides (mmol/L) 1.0 (0.7, 1.5) 1.3 (0.9, 2.0) 1.1 (0.8, 1.6) 4607(82.9) 
LDL Cholesterol (mmol/L)* 2.4 (1.9, 3.0) 2.4 (1.9, 3.0) 2.4 (1.9, 3.0) 2855(51.4) 
HDL Cholesterol (mmol/L) 1.5 (1.2, 1.8) 1.4 (1.1, 1.7) 1.5 (1.2, 1.8) 5283(95.1) 
Ever smoked: Yes 1675 (34.6) 352 (49.3) 2027 (36.5) 5555(99.9) 
Weekly alcohol consumption: units/week    5253 (94.5%) 
    <2 930 (20.2) 234 (35.9) 1164 (22.2)  
   2 — 6 1272 (27.6) 184 (28.3) 1456 (27.7)  
   6 — 14 1310 (28.5) 133 (20.4) 1443 (27.5)  
  14 — 21 607 (13.2) 40 (6.1) 647 (12.3)  
  21 — 32 301 (6.5) 27 (4.1) 328 (6.2)  
  ≥32 182 (4.0) 33 (5.1) 215 (4.1)  
CKDEpi eGFR (ml/min/1.73m²)    5354(96.3) 
    ≥ 90 3242 (69.7) 348 (49.7) 3590 (67.1)  
    60 — 90 1168 (25.1) 242 (34.6) 1410 (26.3)  
    30 — 60 201 (4.3) 79 (11.3) 280 (5.2)  
    <30 43 (0.9) 31 (4.4) 74 (1.4)  
Albuminuria: micro or macro-albuminuria 380 (9.1) 153 (26.1) 533 (11.2) 4775(85.9) 
Ongoing long-term aspirin prescription(>1 yr at 
consent date) 604 (12.5) 190 (26.6) 794 (14.3) 
5558(100.0) 
Ongoing  statin prescription  1863 (38.5) 404 (56.5) 2267 (40.8) 5558(100.0) 
Ongoing anti-hypertensive prescription 1605 (33.1) 403 (56.4) 2008 (36.1) 5558(100.0) 
     
Ever hospitalized for diabetic neuropathy 24 (0.5) 80 (11.2) 104 (1.8) 5558(100.0) 
Current drug prescription for neuropathy (first-
line, as listed in text) 334 (8.7) 419 (46.7) 753 (13.5) 
5558 (100.0) 
Data are presented as median (Interquartile range - IQR: 25th, 75th percentile) or as N (%) 




Table 2 – Logistic regression results for associations between clinical risk factors and DPN 
 
Odds-ratio estimates and associated 95% Confidence Intervals obtained from multivariable logistic regression.  
Statistical significance is denoted by *; ref denotes the reference.  
M1 included all variables with less than 10% missingness whilst M2 included variables with less than 20% missingness. 
Covariates modelled using splines are indicated in italics. All multivariable results from M1, apart from triglycerides and albuminuria 
(M2) 
  
Covariate Univariable Multivariable 
Attained age at baseline (years): 44.7 (median)    
    35 0.61 (0.55,  0.69)* 0.75 (0.63, 0.89)* 
     55 1.46 (1.29, 1.67)* 1.22 (1.00, 1.48)* 
    65 1.50 (1.26,  1.78)* 1.16 (0.87, 1.53) 
Diabetes duration at baseline (years)  1.03 (1.03,   1.04)* 1.02 (1.02, 1.03)* 
Sex: Female (ref: Male) 1.04 ( 0.88,  1.22) 1.19 (0.88, 1.60) 
HbA1c: 53.0 mmol/mol (7%)   
    50.0 mmol/mol (6.7%) 1.07 ( 0.99, 1.14) 1.04 (0.96, 1.13) 
   60.0 mmol/mol (7.6%) 0.94 ( 0.83, 1.07) 0.97 (0.84, 1.13) 
   75.0 mmol/mol (9.0%) 1.79 (1.48,  2.17)* 1.51 (1.21, 1.89)* 
Height (cm) 0.98 (0.97, 1.00) 1.00 (0.98, 1.01) 
Weight (kg) 1.01 (1.00,   1.01) 1.08 (0.91, 1.28) 
BMI 1.03 (1.02,   1.05)*  
Waist-hip ratio 1.50 (1.36, 1.66)* 1.24 (1.08, 1.42)* 
Diastolic Blood Pressure 1.00 (1.00, 1.02) 1.13 (0.94, 1.35) 
Systolic Blood Pressure (mmHg):    130.2  (median) ref ref 
    110 1.91 (1.49,  2.44)* 2.03 (1.43, 2.88)* 
     150 1.52 (1.28, 1.80)*        1.23 (0.98, 1.55) 
HDL Cholesterol (mmol/L) 0.43 (0.34, 0.53)*  0.77 (0.66, 0.89)* 
Total Cholesterol (mmol/L) 1.15 (1.07, 1.24)* 1.11 (1.01, 1.22)* 
Triglycerides (mmol/L) 1.41 (1.31, 1.51)* 1.17 (1.04, 1.31)*  
Albuminuria: Normal ref ref 
     Micro or macro-albuminuria 3.26 (2.62, 4.05)* 1.92 (1.41, 2.63)*  
Typical weekly alcohol consumption (units/week) :<2 units/week ref ref 
2 -6      0.63 (0.50, 0.78)* 0.72 (0.56, 0.92)* 
6-14 0.41 (0.32, 0.52)* 0.54 (0.41, 0.71)* 
14-21 0.28 (0.20, 0.40)* 0.32 (0.21, 0.49)* 
21-32 0.29 (0.19, 0.44)* 0.47 (0.29, 0.75)* 
≥32 0.68 (0.45, 1.02)* 0.88 (0.56, 1.38) 
Ever smoked: Yes (ref: No) 1.73 (1.47, 2.05)* 1.67 (1.37, 2.03)* 
CKDEpi eGFR (ml/min/1.73m²)    :≥ 90 ref ref 
     60 — 90 1.53 (1.25, 1.89)* 1.16 (0.92, 1.46) 
    30 — 60 2.79 (2.03, 3.83)* 1.78 (1.22, 2.59)* 
     <30 4.68 (2.86, 7.66)* 1.96 (1.03, 3.74)* 
Ongoing long-term aspirin prescription: Yes (ref: No) 1.73 (1.41, 2.13)* 1.39 (1.07, 1.79)* 
Ongoing long-term statin prescription: Yes (ref: No) 1.34 (1.11, 1.62)* 0.91 (0.71, 1.17) 
Ongoing long-term anti-hypertensive prescription: Yes (ref: No) 1.89 (1.58, 2.27)* 1.60 (1.26, 2.04)* 




Figure 1 – Directly age-standardized DPN prevalence, by age band and sex, using the European 
Standard Population ESP2013*. 
(*As obtained from https://www.opendata.nhs.scot/dataset/standard-populations/resource/29ce4cda-a831-40f4-af24-636196e05c1a 
[accessed on 30 Sept 2019]) 
Figure 2 – Number of diabetic complications other than neuropathy: distributions by age band (years) 
and DPN status. The complications considered were: nephropathy, prior CVD at baseline, prior PVD at baseline, 
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1 Using the European Standard Population 2013  
Age band (years) Sex N Crude rate Age-standardized rate (95% CI) 
<25 Female 283 7.07 6.89 (4.11 11.00) 
 Male 306 4.25 3.75 (1.83  7.30) 
25-45 Female 987 11.25 11.15 (9.17 13.45) 
 Male 1242 7.89 7.78 (6.30  9.50) 
45-65 Female 951 16.09 16.12 (13.65 18.95) 
 Male 1289 17.46 17.87 (15.58 20.43) 
65-75 Female 175 17.14 17.03 (11.40 24.65) 
 Male 215 21.40 20.63 (14.62 28.66) 
≥75 Female 53 11.32 9.21 (3.22 39.64) 
 Male 57 22.81 19.18 (9.59 84.93) 
Overall  5558 12.86 12.91 (11.78, 16.00) 
Table S2 – Description of complications by DPN status 
Parameter No DPN DPN Total 
Total Included 4843 (87.1) 715 (12.9) 5558 
Any ketoacidosis episodes in the past 12 
months 234 (4.8) 91 (12.7) 325 (5.8) 
Any severe hypoglycaemia episodes in 
the past 12 months 934 (19.3) 249 (34.8) 1183 (21.3) 
Prior CVD 341 (7.0) 199 (27.8) 540 (9.7) 
Retinopathy status at baseline 2232 (55.2) 337 (67.7) 2569 (56.5) 
Mild/Moderate/Referable    
Peripheral vascular disease history at 
baseline 361 (7.5) 259 (36.2) 620 (11.2) 
Nephropathy at baseline 548 (11.4) 227 (31.8) 775 (14.0) 









Figure S1 – Adjusted Odds-ratio for having DPN, by HbA1c at baseline (reference: 53 mmol/mol) and 
associated 95% Confidence Interval Bands – model M1.  
Model M1 is adjusted for all other risk factors, set at representative levels.  
M1 is adjusted for age at baseline (44.7 years), diabetes duration at baseline (20.6 years), sex (male),HbA1c (53 mmol/mol), 
weight (76.9  kg), height(171 cm), waist-hip ratio (0.9), frequency of alcohol consumption exceeding 8 units in one day (never), 
ever smoked (no), CKDEPI-eGFR (≥90 ml/min/1.73m²), systolic blood pressure (13.0.3 mm Hg), diastolic blood pressure (75.7  
mm Hg), HDL-Cholesterol (1.5 mmol/L), total cholesterol (4.6 mmol/L), ongoing long-term aspirin prescription (no), ongoing 
long-term statin prescription (no) and ongoing long-term anti-hypertensive prescription (no). 
 
